Gland Pharma Limited (NSE: GLAND) reported Revenue from Operations of ₹938.28 Crore down from ₹1,063.32 Crore year on year, a decline of 11.8%. Consolidated Net Profit of ₹231.94 Crore, slumped 15% from ₹273 Crore in the same quarter of the previous year. The Earnings per Share is ₹14.08 for this quarter.
Gland Pharma Limited Q3 FY23; Net Profit Down To 232 Crore
Related Post
- Bajaj Finance Ltd Q4 FY24 Earnings Conference Call Insights
Key highlights from Bajaj Finance Ltd (BAJFINANCE) Q4 FY24 Earnings Concall AUM Growth FY24 delivered…
-
SBI Cards & Payment Services Ltd Q4FY24; 11% rise in Profits
SBI Cards and Payment Services Limited is a non-deposit accepting systemically important nonbanking financial company…
-
Bajaj Finance Ltd Q4FY24; 20% rise in Profits
Bajaj Finance is mainly engaged in the business of lending. BFL has a diversified lending…